ArticleChemical science2019
A nano-cocktail of an NIR-II emissive fluorophore and organoplatinum(ii) metallacycle for efficient cancer imaging and therapy.
Article in Chemical science, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed.
- Architecting NIR-II metal supramolecular dyes-illuminating the path to precision medicine.Chemical science · 2026Review
- A Near-Infrared-II Luminescent and Photoactive Vanadium(II) Complex with a 760 ns Excited State Lifetime.Journal of the American Chemical Society · 2025Article
- Nanoprobe-Based Near-Infrared II Optical Imaging for Guiding Precision Glioma Therapy.International journal of nanomedicine · 2025Review
- Inorganic and hybrid nanomaterials for NIR-II fluorescence imaging-guided therapy of Glioblastoma and perspectives.Theranostics · 2025Review
- An ultra-small organic dye nanocluster for enhancing NIR-II imaging-guided surgery outcomes.European journal of nuclear medicine and molecular imaging · 2024Article
- A Novel Multi-Effect Photosensitizer for Tumor Destruction via Multimodal Imaging Guided Synergistic Cancer Phototherapy.International journal of nanomedicine · 2024Article
- Tracking tumor heterogeneity and progression with near-infrared II fluorophores.Exploration (Beijing, China) · 2023Review
- Rationally designed Ru(ii)-metallacycle chemo-phototheranostic that emits beyond 1000 nm.Chemical science · 2022Article
- A nanotheranostic agent based on NdLight, science & applications · 2022Article
- Clearance pathways of near-infrared-II contrast agents.Theranostics · 2022Review
- Editorial: Stimuli-Responsive Emissive Organic and Metal-Organic Compounds.Frontiers in chemistry · 2022Article
- Recent advances in NIR-II fluorescence based theranostic approaches for glioma.Frontiers in chemistry · 2022Review
- Fluorescent probe for the detection of hypochlorous acid in water samples and cell models.RSC advances · 2021Article
- BSA-Coated Gold Nanorods for NIR-II Photothermal Therapy.Nanoscale research letters · 2021Article
- A Near-Infrared-II Emissive Chromium(III) Complex.Angewandte Chemie (International ed. in English) · 2021Article
- Highly Sensitive Fluorescent pH Microsensors Based on the Ratiometric Dye Pyranine Immobilized on Silica Microparticles.Chemistry (Weinheim an der Bergstrasse, Germany) · 2021Article
- Supramolecular coordination complexes as diagnostic and therapeutic agents.Current opinion in chemical biology · 2021Review
- Polymeric Systems Containing Supramolecular Coordination Complexes for Drug Delivery.Polymers · 2021Review
- Recent Progress in Nanomedicine for Melanoma Theranostics With Emphasis on Combination Therapy.Frontiers in bioengineering and biotechnology · 2021Review
- Targeting Contrast Agents With Peak Near-Infrared-II (NIR-II) Fluorescence Emission for Non-invasive Real-Time Direct Visualization of Thrombosis.Frontiers in molecular biosciences · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The scarcity of efficient imaging technologies for precise cancer treatment greatly drives the development of new nanotheranostic based platforms that enable both diagnostic and therapeutic functions, together in a single formulation. Owing to the complicated physiological microenvironment, nanosystems designed with the possibility of noninvasive real-time monitoring of therapeutic progression in the second near-infrared channel (NIR-II, 1000-1700 nm) could substantially improve the current cancer therapies. Herein, we design a novel NIR-II theranostic nanoprobe,
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.